<?xml version="1.0" encoding="UTF-8"?>
<p id="p0520">Alternatively, a virtual screening of FDA-approved drugs was performed against the SARS-CoV-2 Mpro, giving the glecaprevir and maraviroc as the best inhibitors 
 <xref rid="b0715" ref-type="bibr">[143]</xref>. Further, also selected anti-HIV drugs (
 <italic>e.g.</italic>, saquinavir, ritonavir, lopinavir, and others) and anti-HCV drugs (
 <italic>e.g.</italic>, simeprevir, faldaprevir, and asunaprevir) were docked against SARS-CoV-2 Mpro. Indeed, simeprevir (
 <xref rid="f0035" ref-type="fig">Fig. 7</xref>D), an approved HCV NS3/4A protease inhibitor, seems to be a promising lead compound, fitting quite well (-10.0Â kcal/mol) in two hydrophobic pockets flanking the catalytic dyad dyad His41-Cys145 and inducing an opening of the substrate binding pocket, which weakens significantly the compactness of the active site 
 <xref rid="b0720" ref-type="bibr">[144]</xref>.
</p>
